Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib

Asahina, Hajime; Oizumi, Satoshi; Inoue, Akira; Kinoshita, Ichiro; Ishida, Takashi; Fujita, Yuka; Sukoh, Noriaki; Harada, Masao; Maemondo, Makoto; Saijo, Yasuo; Dosaka-Akita, Hirotoshi; Isobe, Hiroshi; Nukiwa, Toshihiro; Nishimura, Masaharu

Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib

Asahina, Hajime; Oizumi, Satoshi; Inoue, Akira et al.

Oncology : International Journal for Cancer Research and Treatment, 2011, 79(5-6), 423-429

Permalink : https://hdl.handle.net/2115/45486

このアイテムのアクセス数:1,447件（2026-10-17 09:57 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
Onc79-5-6_423-429	pdf	244 KB	1,670

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/45486
タイトル	Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib
著者	Asahina, Hajime ; Oizumi, Satoshi ; Inoue, Akira ; Kinoshita, Ichiro ; Ishida, Takashi ; Fujita, Yuka ; Sukoh, Noriaki ; Harada, Masao ; Maemondo, Makoto ; Saijo, Yasuo ; Dosaka-Akita, Hirotoshi ; Isobe, Hiroshi ; Nukiwa, Toshihiro ; Nishimura, Masaharu
e-Rad_Researcher 90374298 著者名 Asahina, Hajime
e-Rad_Researcher 10421968 著者名 Oizumi, Satoshi
著者名 Inoue, Akira
e-Rad_Researcher 40343008 著者名 Kinoshita, Ichiro
著者名 Ishida, Takashi
著者名 Fujita, Yuka
著者名 Sukoh, Noriaki
著者名 Harada, Masao
著者名 Maemondo, Makoto
著者名 Saijo, Yasuo
e-Rad_Researcher 70222528 著者名 Dosaka-Akita, Hirotoshi
e-Rad_Researcher 90241322 著者名 Isobe, Hiroshi
著者名 Nukiwa, Toshihiro
e-Rad_Researcher 00208224 著者名 Nishimura, Masaharu
言語	英語
キーワード	Epidermal growth factor receptor (EGFR)
	Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)
	Gefitinib
	Non-small cell lung cancer (NSCLC)
	Chemotherapy
	readministration
発行日	2011-04
出版者	Karger
収録物名	Oncology : International Journal for Cancer Research and Treatment
巻(号)	79(5-6)
ページ	423-429
抄録	Objective: Salvage treatment for acquired resistance to gefitinib has yet to be developed. We conducted the first prospective phase II study of gefitinib readministration in previous gefitinib responders. Methods: Gefitinib (250 mg/day) was readministered to patients with advanced/metastatic non-small cell lung cancer (NSCLC) who had achieved objective response to initial gefitinib and subsequently received cytotoxic chemotherapy after disease progression with initial gefitinib. The primary endpoint was the objective response rate with gefitinib readministration. Secondary endpoints were disease control rate, progression-free survival (PFS), overall survival (OS), quality of life ((QOL), and toxicity. Changes in lung cancer-related symptoms were evaluated using the seven-item lung cancer subscale of the questionnaire. Results: Sixteen patients were enrolled between February 2005 and January 2008. Most had received ≥ 3 regimens of chemotherapy. Response and disease-control rates for all patients were 0% and 44%. Median PFS and OS were 2.5 months and 14.7 months, respectively. Four of 7 patients with stable disease experienced a long duration (≥ 6 months) of disease control without severe toxicity. Symptom improvement was observed in 2 of 12 patients (17%) for whom QOL was evaluable. Conclusion: Gefitinib represents a useful therapeutic option for selected previous gefitinib responders.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
権利情報	Copyright © 2011 S. Karger AG, Basel
PISSN	0030-2414
関連情報	PMID 21474967
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1159/000326488